Study of immunotherapy in relapsed ALL and LL (2024) An international study shows that the drug daratumumab is safe for children with relapsed T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL).
Cause and biomarker high-risk lymphoma found (Kroeze et al., 2024) Researchers from the Princess Máxima Center have found the most common cause of recurrent T-cell lymphoblastic lymphoma (T-LBL).
Immunotherapy for relapsed Hodgkin lymphoma (Greve et al., 2023) Immunotherapy with nivolumab and brentuximab-vedotin worked well and was well tolerated in children and adolescents with relapsed Hodgkin lymphoma.
Potential benefit CAR T-cell therapy in B-cell non-Hodgkin lymphoma (Minard-Colin et al., 2022) Treatment with tisagenlecleucel may be of benefit to a proportion of children and young adults with B-cell non-Hodgkin's lymphoma (B-NHL) in whom the disease has recurred or failed to respond to previous treatment.
New immunotherapy cures more children with lymphoma (Minard-Colin et al., 2020) A new combination treatment consisting of chemotherapy and the drug rituximab can cure a significant proportion of patients with B-cell non-Hodgkin lymphoma.
Checkpoint inhibitors in the treatment of pediatric solid tumors (Geoerger et al., 2020) In this study researchers determined whether the drug atezolizumab, a so-called checkpoint inhibitor, was active and safe to use in children with solid tumors, including lymphoma.